Future Oncology Journal Issues Research Articles in Part 3 of May 2020 Edition
May 18, 2020
May 18, 2020
LONDON, England, May 18 -- Future Oncology, a journal that says it provides a forum for a new era of cancer care, published research articles, including the following topics, in Part 3 of its May 2020 edition:
* IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
* Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany
. . .
* IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
* Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany
. . .